DOCSLIB.ORG

TAXUS® Express2™ and TAXUS EXPRESS2 ATOM™ Paclitaxel-Eluting Coronary Stent System Layer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
TAXUS® Express2™ and TAXUS EXPRESS2 ATOM™ Paclitaxel-Eluting Coronary Stent System Layer 6.4 Carcinogenicity, Genotoxicity, and Reproductive Toxicology ............5 Table 9.6.7 HORIZONS AMI Secondary Endpoints by Gender ........16 6.5 Pregnancy ....................................................................................................5 Table 9.6.8 HORIZONS AMI Clinical Endpoints, All TAXUS 2012-06 6.6 Lactation ........................................................................................................5 Express® Male and Female Patients at 30 Days, 1 Year, 2 Years 90776901-01 < EN > and 3 Years (Stent ITT Population) ........................................................16 7 OVERVIEW OF CLINICAL STUDIES ....................................................................5 9.7 Pooled Results of the TAXUS SR stent versus BMS (TAXUS I, II-SR, 7.1 TAXUS Clinical Trials ...................................................................................5 IV, and V de novo) .............................................................................................16 ® 2™ Table 7.1 TAXUS Slow-Release Formulation Trials ..............................6 Table 9.7.1 TAXUS SR ITT Patients Disposition Table (N=2793; TAXUS Express 7.2 ARRIVE Clinical Registry .............................................................................6 TAXUS I, II-SR, IV, and V de novo) .........................................................16 8 ADVERSE EVENTS ................................................................................................6 Figure 9.7.1 Efficacy – Target Vessel Revascularization (TVR) in and 8.1 Observed Adverse Events ..........................................................................6 TAXUS pooled analysis (TAXUS I, II-SR, IV, V de novo; N=2793) .....17 Table 8.1 TAXUS V (ISR and de novo), IV, II, and I Major Adverse Figure 9.7.2 Safety – Mortality in TAXUS pooled analysis (TAXUS I, ® 2™ Cardiac Events (MACE) from Post-Procedure to Latest Follow-Up .6 II-SR, IV, V de novo; N=2793) ...................................................................17 TAXUS Express Table 8.2 HORIZONS AMI Major Adverse Cardiac Events (MACE) Figure 9.7.3 Safety – Myocardial Infarction (MI) in TAXUS pooled from Post-Procedure to Latest Follow-Up .............................................7 analysis (TAXUS I, II-SR, IV, V de novo; N=2793) ................................18 ™ 8.2 Potential Adverse Events ..........................................................................7 9.7.1 Stent thrombosis in TAXUS SR pooled analysis (TAXUS I, II-SR, IV, Atom and V de novo; N=2793)...................................................................................18 9 CLINICAL STUDIES ...............................................................................................7 MONORAIL® 9.1. Results of the TAXUS IV Pivotal Clinical Trial ........................................7 Figure 9.7.4 Stent thrombosis Rates for the TAXUS vs. BMS pooled analysis (TAXUS I, II-SR, IV, V de novo; N=2793) vs. BMS by Table 9.1.1 TAXUS IV Clinical Results ......................................................8 Protocol and ARC Definitions .................................................................19 OVER-THE-WIRE Figure 9.1.1 TAXUS IV Freedom from TVR to 5 Years, Event-Free 9.7.2 Diabetic Patients in TAXUS SR pooled analysis (TAXUS I, II-SR, IV, Survival ± 1.5 SE, Safety Population, All Patients (N=1294) ................8 and V de novo; N=715).....................................................................................19 Paclitaxel-Eluting Coronary Stent System Table 9.1.2 TAXUS IV 9-Month Angiographic and IVUS Results........8 Table 9.7.2 Pooled TAXUS SR Clinical Results for Medically Table 9.1.3 TAXUS IV Protocol Defined Stent Thrombosis* through Treated Diabetic Patients (TAXUS I, II-SR, IV, and V de novo) .........19 TABLE OF CONTENTS 5 Years Safety Population (N=1294) ........................................................8 9.8 ARRIVE Clinical Registry ...........................................................................19 WARNING ...................................................................................................................2 9.2 Results of the TAXUS II SR Supporting Clinical Trial ............................8 2 Figure 9.8.1 Lesion complexity in ARRIVE 1 and 2 combined 2 1 TAXUS EXPRESS AND TAXUS EXPRESS ATOM™ PACLITAXEL- Table 9.2.1 TAXUS® II Clinical Results ...................................................9 (N=7492) ......................................................................................................20 ELUTING CORONARY STENT SYSTEM ................................................................2 Figure 9.2.1 TAXUS II Freedom from TVR to 5 Years, Event-Free 9.8.1 ARRIVE 1 ...................................................................................................20 Table 1.1 TAXUS Express2 and TAXUS Express2 Atom Stent System Survival ± 1.5 SE, Intent-to-Treat Population, All Patients (N=267) ...9 Table 9.8.1 ARRIVE 1 - Baseline Demographics and Procedural Product Description ....................................................................................2 9.3 Results of the TAXUS I Feasibility Clinical Trial ......................................9 Characteristics ..........................................................................................20 1.1 Device Component Description ...............................................................2 Table 9.3.1 TAXUS I Clinical Results ........................................................9 Table 9.8.2 ARRIVE 1 Principal Safety Results Summary to 2 years 1.2 Drug Component Description ...................................................................2 Figure 9.3.1 TAXUS I Freedom from TVR to 5 Years, Event-Free (N=2487) ......................................................................................................20 1.2.1 Paclitaxel ...................................................................................................2 Survival ± 1.5 SE, Safety population (N=61) ...........................................9 Table 9.8.3 Stent Thrombosis by Time Interval in ARRIVE 1 Figure 1.1 The Chemical Structure of Paclitaxel ..................................2 9.4 TAXUS V – De Novo Expansion Clinical Trial..........................................9 (N=2487) ......................................................................................................20 1.2.2 Translute Polymer Carrier .......................................................................2 Table 9.4.1 TAXUS V de novo Baseline Characteristics ....................10 9.8.2 ARRIVE 2 ...................................................................................................20 Figure 1.2 The Chemical Structure of Translute Polymer Carrier ......2 Table 9.4.2 TAXUS V de novo Clinical Results .....................................10 Table 9.8.4 ARRIVE 2 - Baseline Demographics and Procedural 1.2.3 Product Matrix and Paclitaxel Content ...............................................2 Figure 9.4.1 TAXUS V Freedom from TVR to 5 Years, Event-Free Characteristics ..........................................................................................21 Table 1.2 TAXUS Express2 Stent System Product Matrix and Survival ± 1.5 SE, Safety Population, All Patients (N=1146) ..............10 Table 9.8.5 ARRIVE 2 Principal Safety Results Summary to 2 Years Paclitaxel Content .......................................................................................2 Table 9.4.3 TAXUS V de novo Workhorse Subgroup (N=5005) ......................................................................................................21 2 INTENDED USE/INDICATIONS FOR USE..........................................................3 (one implanted 2.5 mm, 3.0 mm, or 3.5 mm diameter study stent) Table 9.8.6 Stent Thrombosis by Time Interval in ARRIVE 2 Clinical Results ..........................................................................................11 (N=5005) ......................................................................................................21 3 CONTRAINDICATIONS.........................................................................................3 Table 9.4.4 TAXUS V de novo 2.25 mm Diameter Stent Clinical 9.9 Subgroup analysis of the ARRIVE registries ........................................21 4 WARNINGS ............................................................................................................3 Results .........................................................................................................11 Table 9.9.1 Subgroup Outcomes in Pooled ARRIVE 1 and 2 (0-1 5 PRECAUTIONS .......................................................................................................3 Table 9.4.5 Patients with Lesion Length > 26 mm by Visual year) .............................................................................................................21 5.1 General Precautions ...................................................................................3 Estimate and ≥ 2 Planned Stents Clinical Results ..............................11 Table 9.9.2 Subgroup Outcomes in Pooled ARRIVE 1 and 2 (1-2 5.2 Pre-and Post-Procedure Antiplatelet Regimen ....................................3 Table 9.4.6 TAXUS V de novo Large Vessel Sub-Group (4.0 mm years) ...........................................................................................................22 5.2.1 Oral Antiplatelet Therapy ........................................................................3 diameter stent)
Load more

Recommended publications
  • TAXUS™ Liberte™ Paclitaxel-Eluting Coronary Stent
    TAXUS® Express2 ™ Paclitaxel-Eluting Coronary Stent System TAXUS® Liberté® Paclitaxel-Eluting Coronary Stent System A Patient’s Guide Table of Contents Coronary Artery Disease ........................................................................................................... 2 Who Is at Risk? .................................................................................................................. 3 Diagnosis of Coronary Artery Disease ................................................................................ 3 Treatment of Coronary Artery Disease ...................................................................................... 3 Angioplasty ......................................................................................................................... 4 Coronary Artery Stents ....................................................................................................... 4 Restenosis ........................................................................................................................... 5 Your Drug-Eluting Stent ........................................................................................................... 7 Drug-Eluting Stents ........................................................................................................... 7 The Express® Stent and Liberté® Stent Platforms for the TAXUS® Stent ............................ 7 The Polymer Coating on the TAXUS Stent ....................................................................... 8 The Drug That Is
    [Show full text]
  • View Annual Report
    2007 ANNUAL REPORT Profile of a Global Leader • One of the world’s largest medical device companies, with $8.357 billion in sales • Sales in more than 100 countries • Portfolio of approximately 13,000 products, many with #1 positions • A global leader in cardiovascular medicine $8,357 $7,821 • #1 worldwide in drug-eluting stent market • 24 million products shipped $6,283 • More than 13,800 patents issued worldwide $5,624 • More than $1 billion invested in R&D A Better Future. LEARN HOW WE’RE BUILDING IT. • 37 manufacturing, distribution and technology centers worldwide $3,476 $2,842 $2,919 $2,664 $2,673 $2,234 $1,831 $1,551 $1,191 $449 $315 $380 92 93 94 95 96 97 98 99 00 01 02 03 04 05 06 07 Revenue in millions | Years Boston Scientific Corporation One Boston Scientific Place Natick, MA 01760-1537 508.650.8000 www.bostonscientific.com Note: Information above is accurate as of December 31, 2007. Copyright © 2008 by Boston Scientific Corporation or its affiliates. All rights reserved. BSCAR2008 32737CVR.indd 1 3/14/08 3:38:46 PM Corporate Information EXECUTIVE OFFICERS AND DIRECTORS Uwe E. Reinhardt, Ph.D. 1,3,5 ANNUAL MEETING John E. Abele Director; Professor of Economics and Public Affairs, The annual meeting for shareholders will take Director; Founder Princeton University place on Tuesday, May 6, 2008, beginning In 2007, Boston Scientifi c made signifi cant progress toward restoring sustainable and more profi table 2,6 at 10:00 a.m. at Harvard Club of Boston, 374 Donald S.
    [Show full text]
  • TAXUS™ Express 2 ™ Paclitaxel-Eluting
    TAXU S ® Express 2® Paclitaxel-Eluting Coronary Stent System Patient Information Guide Table of Contents Notes Coronary Artery Disease . 2 Who is at Risk? . .3 Diagnosis of Coronary Artery Disease . 3 Treatment of Coronary Artery Disease . 3 Angioplasty . 4 Coronary Artery Stents . 4 Restenosis . 5 Your Drug-Eluting Stent, the TAXUS ® Express 2® Paclitaxel-Eluting Coronary Stent System . 7 Drug-Eluting Stents . 7 The Express ® Stent Platform for the TAXUS ® Express ® Stent . 7 The Polymer Coating on the TAXUS Express Stent . 7 The Drug that is Released from the TAXUS Express Stent . 8 When should the TAXUS Express Stent NOT be Used . 8 What are the Risks & Potential Benefits of Treatment with the TAXUS Express Stent? . 9 Alternative Practices and Procedures . 11 The Angioplasty Procedure . 12 Preparation for the Procedure . 12 Angioplasty and Stent Placement Procedure . 12 Post-Treatment . 13 After the Procedure . 13 Activity . 14 Medications . 14 Follow-Up Examinations . 15 Magnetic Resonance Imaging (MRI) . 15 Frequently Asked Questions . 16 Glossary . 17 Patient Information Card . Inside Back Cover 1 Notes Coronary Artery Disease Coronary Artery Disease (CAD) is usually caused by atherosclerosis, and affects the coronary arteries that surround the heart. These coronary arteries supply blood with oxygen and other nutrients to the heart muscle to make it function properly. CAD occurs when the inner walls of the coronary arteries thicken due to a buildup of cholesterol, fatty deposits, calcium, and other elements. This material is known as plaque. As plaque develops, the vessel narrows. When the vessel narrows (for example with physical exertion or mental stress), Aorta blood flow through the vessel is reduced so less oxygen and Right Left other nutrients reach Coronary Coronary the heart muscle.
    [Show full text]
  • Bsx-2020-Jpm-Presentation-Final.Pdf
    Mike Mahoney Chairman and Chief Executive Officer Safe harbor for forward-looking statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend” and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could differ materially from the expectations and projections expressed or implied by our forward-looking statements. Factors that may cause such differences can be found in our most recent Form 10-K and Forms 10-Q filed or to be filed with the Securities and Exchange Commission under the headings “Risk Factors” and “Safe Harbor for Forward-Looking Statements.” Accordingly, you are cautioned not to place undue reliance on any of our forward-looking statements. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which they may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. 2 Regulatory disclaimers Product Regulatory Disclaimer WATCHMAN FLX™ CE Marked. U.S.: Caution: Investigational Device. Limited by Federal (or U.S.) law to investigational use only.
    [Show full text]
  • ANALYSIS of AGREEMENT CONTAINING CONSENT ORDER to AID PUBLIC COMMENT in the Matter of Boston Scientific Corporation and Guidant Corporation File No
    ANALYSIS OF AGREEMENT CONTAINING CONSENT ORDER TO AID PUBLIC COMMENT In the Matter of Boston Scientific Corporation and Guidant Corporation File No. 061 0046 The Federal Trade Commission (“Commission”) has accepted, subject to final approval, an Agreement Containing Consent Order (“Consent Agreement”) from Boston Scientific Corporation (“Boston Scientific”). The purpose of the proposed Consent Agreement is to remedy the anticompetitive effects that would otherwise result from Boston Scientific’s acquisition of Guidant Corporation (“Guidant”). Under the terms of the proposed Consent Agreement, Boston Scientific and Guidant are required: (a) to divest all assets (including intellectual property) related to Guidant’s vascular business to a third party, enabling that third party to make and sell drug eluting stents (“DESs”) with the Rapid Exchange (“RX”) delivery system; Percutaneous Transluminal Coronary Angioplasty (“PTCA”) balloon catheters; and coronary guidewires, and (b) to reform Boston Scientific’s contractual rights with Cameron Health, Inc. (“Cameron”) to limit Boston Scientific’s control over certain Cameron actions and the sharing of non-public information about Cameron’s Implantable Cardioverter Defibrillator (“ICD”) product. The proposed Consent Agreement has been placed on the public record for thirty days to solicit comments from interested persons. Comments received during this period will become part of the public record. After thirty days, the Commission will again review the proposed Consent Agreement and the comments received, and will decide whether it should withdraw the proposed Consent Agreement or make it final. Pursuant to an Agreement and Plan of Merger dated January 25, 2006, Boston Scientific proposes to acquire Guidant in exchange for cash and voting securities in a transaction valued at approximately $27 billion.
    [Show full text]
  • BSX Investor Day 2019 Full Presentation
    Susan Lisa Vice President, Investor Relations Safe harbor for forward-looking statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend” and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could differ materially from the expectations and projections expressed or implied by our forward-looking statements. Factors that may cause such differences can be found in our most recent Form 10-K and Forms 10-Q filed or to be filed with the Securities and Exchange Commission under the headings “Risk Factors” and “Safe Harbor for Forward-Looking Statements.” Accordingly, you are cautioned not to place undue reliance on any of our forward-looking statements. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which they may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. Regulatory disclaimers Product Regulatory Disclaimer EXALT™ Model D Not available for sale, currently pending 510(k) clearance in the US. SpyGlass™ Discover Device under development.
    [Show full text]
  • 2020 Annual Report Boston
    BOSTON REPORT SCIENTIFIC 2020 ANNUAL 2020 Annual Report Boston Scientific Corporation 300 Boston Scientific Way Marlborough, MA 01752-1234 bostonscientific.com © 2021 Boston Scientific Corporation or its affiliates. All rights reserved. AR2020 23006_031221_10k_Cover.indd 1 3/15/21 1:02 PM Board of Directors Executive Officers Stockholder Information Nelda J. Connors 2,4 Daniel J. Brennan Stock Listing Certifications of the Chief Founder and Chief Executive Vice President Boston Scientific Corporation Executive Officer and Chief Executive Officer, Pine and Chief Financial Officer common stock is traded on the Financial Officer certifying the Grove Holdings, LLC NYSE under the symbol “BSX.” accuracy of the Company’s Arthur C. Butcher public disclosures have been 1,4 Executive Vice President Charles J. Dockendorff Transfer Agent filed with the Securities and and President, Asia Pacific Former Executive Vice Inquiries concerning the Exchange Commission as President and Chief transfer or exchange of Wendy Carruthers exhibits to the Company’s Financial Officer, shares, lost stock certificates, Senior Vice President, Annual Report on Form Covidien plc duplicate mailings, or changes Human Resources 10-K for the year ended of address should be directed Yoshiaki Fujimori 4 December 31, 2020. Jodi Euerle Eddy to the Company’s Transfer Senior Executive Advisor Senior Vice President and Agent at: Copies of these reports are of Japan, CVC Capital Chief Information and also available by directing Partners Computershare Inc. Digital Officer requests to: P.O. Box 30170 Donna A. James 2,3 Investor Relations Joseph M. Fitzgerald College Station, TX 77842-3170 Founder, President Boston Scientific Corporation Executive Vice President and Managing Director, Shareholder website: 300 Boston Scientific Way and President, Interventional Lardon & Associates, LLC www.computershare.com/ Marlborough, MA 01752-1234 Cardiology investor 508-683-4000 Edward J.
    [Show full text]
  • Drug-Eluting Stents in Elderly Patients with Coronary Artery Disease (SENIOR): a Randomised Single-Blind Trial
    Articles Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial Olivier Varenne, Stéphane Cook, Georgios Sideris, Sasko Kedev, Thomas Cuisset, Didier Carrié, Thomas Hovasse, Philippe Garot, Rami El Mahmoud, Christian Spaulding, Gérard Helft, José F Diaz Fernandez, Salvatore Brugaletta, Eduardo Pinar-Bermudez, Josepa Mauri Ferre, Philippe Commeau, Emmanuel Teiger, Kris Bogaerts, Manel Sabate, Marie-Claude Morice, Peter R Sinnaeve, for the SENIOR investigators Summary Published Online Background Elderly patients regularly receive bare-metal stents (BMS) instead of drug-eluting stents (DES) to shorten November 1, 2017 http://dx.doi.org/10.1016/ the duration of double antiplatelet therapy (DAPT). The aim of this study was to compare outcomes between these S0140-6736(17)32713-7 two types of stents with a short duration of DAPT in such patients. See Online/Comment http://dx.doi.org/10.1016/ Methods In this randomised single-blind trial, we recruited patients from 44 centres in nine countries. Patients were S0140-6736(17)32803-9 eligible if they were aged 75 years or older; had stable angina, silent ischaemia, or an acute coronary syndrome; and had at Hôpital Cochin, Assistance least one coronary artery with a stenosis of at least 70% (≥50% for the left main stem) deemed eligible for percutaneous Publique—Hôpitaux de Paris, coronary intervention (PCI). Exclusion criteria were indication for myocardial revascularisation by coronary artery bypass Paris, France, and Cardiology Department, Université Paris grafting; inability to tolerate, obtain, or comply with DAPT; requirement for additional surgery; non-cardiac comorbidities Descartes, Sorbonne Paris-Cité, with a life expectancy of less than 1 year; previous haemorrhagic stroke; allergy to aspirin or P2Y12 inhibitors; contraindication Paris, France (Prof O Varenne MD); Cardiology to P2Y12 inhibitors; and silent ischaemia of less than 10% of the left myocardium with a fractional flow reserve of 0·80 or higher.
    [Show full text]
  • Angioplasty and Stent Education Guide
    Angioplasty and Stent Education Guide Table of Contents Treating coronary artery disease . 2 What is coronary artery disease . 3 Coronary artery disease treatment options . 4 What are coronary artery stents . 6 What are the different types of coronary stents . 7 How does the drug coating and polymer work on the SYNERGYTM bioabsorbable polymer drug-eluting stent? . 8 Risks of treatment options . 9 Before your coronary artery stenting procedure . 12 During a typical coronary artery stenting procedure . 13 After a typical coronary artery stenting procedure . 14 Medications . 15 Frequently asked questions . 16 Glossary . 17 1 Treating coronary artery disease Your doctor may want you to have a stent placed in your coronary artery . This is to help treat your coronary artery disease . This guide explains the procedure and what you can expect from start to finish . A glossary at the end of this guide defines common medical terms related to this procedure . You will also learn steps you can take to live a healthier life with coronary artery disease . 2 What is coronary artery disease? Coronary Artery Disease (CAD) is the narrowing of the arteries in the heart . This narrowing can also be called stenosis . It is usually Aorta Left caused by a build up of fat or calcium deposits called plaque . Over Coronary Right Artery time, this plaque can build to a total blockage of the artery . This Coronary process is called atherosclerosis . Artery Circumflex Artery When the heart doesn’t receive enough blood flow due to blockage in the artery, it may cause mild to severe chest pain or pressure .
    [Show full text]
  • Angioplasty and Stent Education Guide
    Angioplasty and Stent Education Guide Table of Contents Treating coronary artery disease ......................................... 2 What is coronary artery disease?.......................................... 3 Coronary artery disease treatment options ................................. 4 What are coronary artery stents?.......................................... 6 What are the different types of coronary stents?............................. 7 How does the drug coating and polymer work on a drug-eluting stent? ......... 7 Risks of treatment options ............................................... 8 Before your coronary artery stenting procedure ............................ 11 During a typical coronary artery stenting procedure ........................ 12 After a typical coronary artery stenting procedure .......................... 13 Medications .......................................................... 14 Frequently asked questions ............................................. 15 Glossary ............................................................. 16 FOLD Treating coronary artery disease Your doctor may want you to have a stent placed in your coronary artery. This is to help treat a blockage in your artery that is caused by coronary artery disease. This guide explains the stent procedure and what you can expect from start to finish. A glossary at the end of this guide defines common medical terms related to this procedure. You will also learn steps you can take to live a healthier life with coronary artery disease. 2 FOLD FOLD What is coronary artery disease? Coronary artery disease (CAD) is the narrowing of the arteries in the heart. This narrowing can also be called stenosis. It is usually Aorta Left Coronary caused by a build up of fat or calcium deposits called plaque. Over Right Artery time, this plaque can build to a total blockage of the artery. This Coronary process is called atherosclerosis. Artery Circumflex When the heart doesn’t receive enough blood flow due to blockage Artery in the artery, it may cause mild to severe chest pain or pressure.
    [Show full text]
  • Boston Scientific / Guidant Regulation
    EN Case No COMP/M.4076 - BOSTON SCIENTIFIC / GUIDANT Only the English text is available and authentic. REGULATION (EC) No 139/2004 MERGER PROCEDURE Article 6(1)(b) NON-OPPOSITION Date: 11/04/2006 In electronic form on the EUR-Lex website under document number 32006M4076 Office for Official Publications of the European Communities L-2985 Luxembourg COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 11/04/2006 SG-Greffe(2006) D/202010 In the published version of this decision, some PUBLIC VERSION information has been omitted pursuant to Article 17(2) of Council Regulation (EEC) No 4064/89 concerning non-disclosure of business secrets and other confidential information. The omissions are shown thus […]. Where possible the information MERGER PROCEDURE omitted has been replaced by ranges of figures or a general description. ARTICLE 6(1)(b) DECISION To the notifying party Dear Sir/Madam, Subject: Case No COMP/M.4076-Boston Scientific/Guidant Notification of 23.02.2006 pursuant to Article 4 of Council Regulation No 139/20041 1. On 23.02.2006, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 by which the undertaking Boston Scientific Corporation (“Boston Scientific”, USA) acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of the undertaking Guidant Corporation (“Guidant”, USA), with the exception of Guidant’s interventional cardiology and endovascular devices businesses, by way of purchase of shares. 2. The Commission has concluded that the notified operation falls within the scope of the Merger Regulation and does not raise serious doubts as to its compatibility with the common market and with the functioning of the EEA Agreement.
    [Show full text]
  • Boston Scientific Corp
    Krause Fund Research Spring 2020 April 15, 2020 Boston Scientific Corporation (NYSE: BSX) NO ACTION Health care – Medical Devices Stock Rating: Analysts Andrew Chelmowski BenJamin Gardner [email protected] [email protected] Current Price: $35.92 Target Price Range: $40 -$53 Investment Thesis DCF & EP IntrinsicStock Values Value: $48 We recommend a neutral, no action rating for Boston Scientific Corporation. BSX features promising long-term growth goals and is a leading player in the advancements of Interventional Cardiology. However, with a highly Key Statistics competitive landscape and global supply chain disruption due to COVID-19, Market Cap $49.2 B we recommend no action at this time. Drivers of Thesis Shares Outstanding 1.39 B 52 Week High-Low $46.6 - $24.10 § Long-Term Growth Goals: In 2019, BSX gave guidance on their long- term growth plans, centered around category leadership and product Beta inancial Ratios 1.08 diversification into faster12-growth-Month Performance markets. R & D spending was P/E Ratio 20E 23.5 approximately $1 Billion dollars, showing their dedication to their long- term growth strategy. Industry Metrics R&D (% of Sales) 11.51% § Foundation of Successful products: Successful products have positioned BSX well to continue expanding. The WATCHMAN, an ROE 20E 13.96% appendage closure device, continues to serve the Cardiovascular ROA 20E 11.88% segment extremely well, while the ACURATERelative Financial Performance Valve, LOTUS Edge, and Millipede all continue to serve the Rhythm Neuro and MedSurg Financial Ratios segments with positive growth rates. Current Ratio 1.89 Risks to Thesis Debt-to-Equity 1.12 § Competitive Landscape: BSX operates in several markets including Company Description Cardiovascular, CRM, Endoscopy and Neuromodulation where its Boston Scientific Corporation (NYSE: BSX), face-to-face with larger, well-capitalized companies like Johnson & headquartered in Natick, Massachusetts Johnson, Abbot, and Medtronic.
    [Show full text]